Diseases / Constipation
Constipation
DiseaseConstipation is a gastrointestinal condition characterized by infrequent bowel movements, hard stools, or difficulty passing stools, often associated with dietary, behavioral, or medical factors.
- Trials
- 798
- Recruiting
- 56
- Completed
- 520
- With results
- 129
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Suspended | Unknown | No longer available | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | — | — | — | — | 6 | — | 1 | — | — | — | 7 |
| Phase 1 | — | — | — | — | 21 | — | — | — | — | — | 21 |
| Phase 1/2 | 1 | 4 | — | 1 | 12 | — | — | — | 1 | — | 19 |
| Phase 2 | 4 | 2 | — | 4 | 70 | 5 | 1 | — | 2 | — | 88 |
| Phase 2/3 | 1 | 1 | — | — | 9 | 2 | — | — | 4 | — | 17 |
| Phase 3 | — | 2 | — | 2 | 58 | 11 | 3 | 1 | 10 | — | 87 |
| Phase 4 | 4 | — | — | — | 62 | 11 | 4 | — | 8 | — | 89 |
| Not applicable | 37 | 17 | 2 | 8 | 225 | 10 | 7 | — | 49 | — | 355 |
| Unknown | 9 | 7 | 2 | 4 | 57 | 6 | 6 | 1 | 22 | 1 | 115 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Constipation | 7 | 21 | 19 | 88 | 17 | 87 | 89 | 355 | 115 | 798 |
| Diarrhea | 1 | — | 4 | 8 | — | 2 | 4 | 23 | 16 | 58 |
| Irritable Bowel Syndrome | — | 2 | 4 | 9 | 1 | 7 | 2 | 9 | 14 | 48 |
| Fecal Incontinence | 2 | — | — | 1 | — | 1 | 3 | 14 | 11 | 32 |
| Abdominal Pain | 1 | — | 1 | 2 | — | 3 | 1 | 17 | 6 | 31 |
| Opioid-Induced Constipation | — | 3 | — | 11 | 2 | 9 | 1 | 2 | 1 | 29 |
| Pain | — | — | 1 | 5 | 1 | 9 | 4 | 4 | 3 | 27 |
| Parkinson Disease | — | 2 | 1 | 4 | — | 1 | 1 | 16 | 1 | 26 |
| Gastroesophageal Reflux | — | — | — | — | — | 1 | — | 10 | 5 | 16 |
| Neoplasms | — | — | — | 5 | — | — | 2 | 3 | 5 | 15 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | Movetis | 17 | 6 |
| 2 | Bausch Health Americas, Inc. | 15 | 7 |
| 3 | Braintree Laboratories | 15 | 3 |
| 4 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 12 | 7 |
| 5 | Mayo Clinic | 12 | 0 |
| 6 | Augusta University | 9 | 0 |
| 7 | Medical University of Warsaw | 8 | 2 |
| 8 | Kissei Pharmaceutical Co., Ltd. | 7 | 4 |
| 9 | Massachusetts General Hospital | 7 | 2 |
| 10 | Novartis | 7 | 4 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | prucalopride | 27 |
| 2 | polyethylene glycol 3350 | 26 |
| 3 | Probiotics | 21 |
| 4 | Lubiprostone | 17 |
| 5 | Polyethylene Glycols | 17 |
| 6 | Lactulose | 12 |
| 7 | maltodextrin | 12 |
| 8 | Bisacodyl | 11 |
| 9 | methylnaltrexone | 11 |
| 10 | Sennosides | 11 |
Evidence
- Results reported
- 24.8%129 of 520 completed
- Published
- 14%73 of 520 completed
- Primary endpoint met
- 47.3%43 of 91 analyses
- Median months to report
- 17
Documents disclosed
Trial profile
- Median enrollment
- 74
- Median duration
- 17months
- Countries
- 61
- Study sites
- 4407
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 20
- Phase 1
- 34
- Phase 1/2
- 52
- Phase 2
- 87
- Phase 2/3
- 81
- Phase 3
- 225
- Phase 4
- 70
- Not applicable
- 60
- Unknown
- 101
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | Boston | United States | 40 |
| 2 | Houston | United States | 39 |
| 3 | Miami | United States | 33 |
| 4 | Tampa | United States | 32 |
| 5 | Winston-Salem | United States | 32 |
| 6 | Tucson | United States | 31 |
| 7 | Phoenix | United States | 30 |
| 8 | Chicago | United States | 29 |
| 9 | Cincinnati | United States | 29 |
| 10 | Chattanooga | United States | 28 |
Terminations
- Terminated
- 45
- Withdrawn
- 22
- Suspended
- 2
- Stopped for recruitment
- 3.3%26 of 798 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT04031469 Suspended | Suspended | Administrative | 2030-12-10 |
| NCT04148248 Withdrawn | Withdrawn | Company shifted focus | 2030-07-31 |
| NCT06924957 Terminated | Terminated | Low rate of enrolment of patients in control group | 2026-08-17 |
| NCT05566171 Withdrawn | Withdrawn | My colleague did not want to continue the study | 2025-03-30 |
| NCT05734833 Withdrawn | Withdrawn | lack of enrollment | 2025-02-18 |
| NCT04759833 Terminated | Terminated | Data Monitoring Committee (DMC) decision; terminated due to futility, with no safety concerns; FDA agreement to terminate the study. | 2023-11-13 |
| NCT05723731 Terminated | Terminated | A pre-specified interim analysis was conducted as planned, we calculated a P-value greater than 0.57 when comparing response rates between taVNS and sham group, resulting in an early termination of the study. | 2023-09-28 |
| NCT04768010 Withdrawn | Withdrawn | After significant delays study was never initiated. No participants enrolled | 2023-09-18 |
| NCT05082129 Withdrawn | Withdrawn | due to the impact of the COVID19 pandemic on MRI service provision, NHS hospitals were unable to provide the resources to conduct the study | 2023-07-12 |
| NCT05321953 Withdrawn | Withdrawn | Difficulty recruiting | 2023-05-10 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above: